Pamapimod
A pharmaceutical drug used in the treatment of rheumatoid arthritis
Pamapimod is a pharmaceutical compound that was investigated for its potential use in the treatment of rheumatoid arthritis. It is classified as a selective inhibitor of p38 mitogen-activated protein kinases (MAPKs), which are enzymes involved in the inflammatory response.
Mechanism of Action[edit | edit source]
Pamapimod functions by inhibiting the activity of p38 MAPK, a key enzyme in the signaling pathways that lead to the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). By blocking this pathway, pamapimod reduces inflammation and the associated symptoms of rheumatoid arthritis.
Development and Clinical Trials[edit | edit source]
Pamapimod was developed by Hoffmann-La Roche, a global healthcare company. During its development, pamapimod underwent several clinical trials to assess its efficacy and safety in patients with rheumatoid arthritis. These trials aimed to determine the optimal dosing regimen and to evaluate the drug's impact on disease activity and progression.
Phase I Trials[edit | edit source]
In the initial phase of clinical testing, pamapimod was evaluated for its safety, tolerability, and pharmacokinetics in healthy volunteers. These studies helped establish the appropriate dosage levels for further testing.
Phase II Trials[edit | edit source]
Subsequent trials involved patients with active rheumatoid arthritis. The primary endpoints included reduction in disease activity scores and improvement in physical function. While some studies showed promising results, others indicated limited efficacy compared to existing treatments.
Challenges and Discontinuation[edit | edit source]
Despite initial promise, the development of pamapimod faced challenges. The drug's efficacy in reducing symptoms of rheumatoid arthritis was not consistently superior to existing therapies, and there were concerns about potential side effects. As a result, further development was eventually discontinued.
Potential Applications[edit | edit source]
Although pamapimod is no longer being developed for rheumatoid arthritis, its mechanism of action as a p38 MAPK inhibitor continues to be of interest in the field of inflammatory diseases. Research into similar compounds may lead to new treatments for conditions characterized by excessive inflammation.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
